anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medical implant includes a bioerodible portion that includes a bioerodible polymer and a bioerodible metal. The bioerodible polymer matrix degrades under physiological conditions to form acidic degradation products. The bioerodible metal degrades under physiological conditions to form basic degradation products. The acidic degradation products and the basic degradation products buffer at least a portion of the medical implant. In one aspect, the bioerodible portion includes a bioerodible polymer matrix and a bioerodible metal within the bioerodible polymer matrix. In another aspect, the medical implant can include a body, a plurality of discrete deposits of the bioerodible polymer on the body, and a plurality of discrete deposits of the bioerodible metal on the body.
Background: Sepsis, defined as life-threatening organ dysfunction due to a dysregulated host response to infection, continues to be a source of considerable morbidity and mortality. 19 million cases are seen worldwide each year. Many animal sepsis models had found that sepsis induced multiple organ failure. Ubiquitination, autophagy, apoptosis may involve the process of sepsis related multiple organ failure. Mass spectrometry-based proteomics studies in clinical populations and in rodent and mammalian animal models had started with discovered many novel biomarkers of sepsis. Esoxomes had been found in blood or urine presented the signal of autophagy and apoptosis. Recently, nanoparticle tracking analysis (NTA) was used as a new method for direct and real-time analysis of exosomes. These make it possible to study the exosome biomarkers to analyze septic patients with multiple organ failure.

Aims of the study: This research will be the first study not only to set up macrophage co-cultured with human organ cell models for exosomes secretions but also collect purified exosomes in blood and urine from septic patients. Proteomics studies in exosomes from cell culture and clinical specimens. Analyze ubiquitination, autophage, and apoptosis related biomarkers of exosomes by bioinformatics. Use NTA to set up newly diagnostic methods, to judge the specific organ damage of septic patient by exosomes autophagy-apoptosis biomarkers.

Materials and Methods: In 1st year, LPS (lipopolysaccharide) stimulated macrophage co-cultured with human organ cells will be set up. Exosomes will be isolated and purified from different groups. ScFv (single chain fragments of antibody) will be selected for blocking infection related exosome's transmission. The 2nd year, a total of 60 patients with infection and positive culture results will be included, of whom 30 septic patients had at least one organ failure, others will have only infection. All patients included and classified according to the sepsis-3 criteria. Clinical specimens will be collected from August 2017 to July 2019. Exosome will be isolated and purified. Magnetic beads purification, 2D gel electrophoresis, MALDI-TOF, and bioinformatics will be used to analyze proteomics of exosomes and association of organ-specific markers, autophagy, and apoptosis markers. Western blotting will be done to prove the proteins found by proteomics. Cytokines array in blood also confirm and correlate to autophagy. Finally, we will use nanoparticle tracking analysis with double markers identification to understand the exosome subpopulations of specific organ and autophagy-apoptosis biomarkers.

Possible effect: Systematic establishment of exosome proteomics in co-culture medium and clinical sepsis specimens will be done. In vitro study, ScFv exploring will help to block exsomes uptake as a possible therapeutic method. Ubiquitination-autophagy-apoptosis biomarkers in exosomes will be detected and correlated to specific organ failure in sepsis. The inflammatory process also will be validated by cytokines analysis. NTA double markers identification will be a smart method to understand the exosome subpopulations.
BACKGROUND: Both dementia and frailty have been associated with worse outcomes in patients with hip fractures. However, the interrelation and predictive value of these two entities has yet to be clarified. The current study aimed to investigate the predictive relationship between dementia, frailty, and in-hospital mortality after hip fracture surgery.
METHODS: All patients registered in the 2019 National Inpatient Sample Database who were 50 years or older and underwent emergency hip fracture surgery following a traumatic fall were eligible for inclusion. Logistic regression (LR) models were constructed with in-hospital mortality as the response variables. One model was constructed including markers of frailty and one model was constructed excluding markers of frailty [Orthopedic Frailty Score (OFS) and weight loss]. The feature importance of all variables was determined using the permutation importance method. New LR models were then fitted using the top ten most important variables. The area under the receiver-operating characteristic curve (AUC) was used to compare the predictive ability of these models.
RESULTS: An estimated total of 216,395 patients were included. Dementia was the 7th most important variable for predicting in-hospital mortality. When the OFS and weight loss were included, they replaced dementia in importance. There was no significant difference in the predictive ability of the models when comparing the model that included markers of frailty [AUC for in-hospital mortality (95% CI) 0.79 (0.77-0.81)] with the model that excluded markers of frailty [AUC for in-hospital mortality (95% CI) 0.79 (0.77-0.80)].
CONCLUSION: Dementia functions as a surrogate for frailty when predicting in-hospital mortality in hip fracture patients. This finding highlights the importance of early frailty screening for improvement of care pathways and discussions with patients and their families in regard to expected outcomes.
It will be a randomized, double-blind, two arm clinical study to assess effect of atorvastatin 40 mg treatment in patients with stable COPD. The whole study duration will include three phases: pre-study screening and enrollment procedures (4 weeks), clinical assessment at dosing (52 weeks), and post study follow up (4 weeks). During the participation in the study subjects will attend Visit 1 (V1, -4 weeks), visit 2 (V2, day 0), visit 3 (V3, week6), visit 4 (V4, week 12), visit 5 (V5, week 26), visit 6 (V6, week 38), visit 7 (V7, week 52), and follow-up end of study visit (EOS, 56 weeks). The study will begin with a 4-weeks screening phase where patients who fulfill preliminary inclusion/exclusion criteria (prior to entry into study), will be given informed consent and screened. The baseline laboratory tests, clinical and medical evaluation including concomitant medication and drug of abuse will be completed to determine patient continuing eligibility to participate in the study.

Upon confirmation of eligibility, the patients will be randomized into two treatment groups receiving one of two medications tested in the study. Each patient enrolled into the clinical study will have to report to the clinic 7 times in order to complete procedures. Blood will be drawn before and during the statin or placebo treatment from patients according to study protocol. This part of the project aims to develop statin response biomarkers for personalized treatment of COPD, based on RNA-sequencing (RNA-seq) information derived from, leukocytes and blood plasma of COPD patients with characterized clinical Atorvastatin response phenotypes.
Will be evaluated at baseline and will be intervened for 7 weeks, receiving educational workshops twice a week, addressing the target behaviors. They will also be prescribed a personalized food plan, will receive daily messages through the mobile application, and will have a doubt resolution chat. They will have a digital forum to post photos and comments about their food intake, and physical activity performance, and to like and comment on other participants' photos. They will be asked to enter food records and photos of their food intake into the mobile application, for which they will receive points for performing the expected behavior in a token economy. They will have access to their data for auto-monitoring. In week 8, the experimental group will be evaluated and divided into two sub-groups. One will be completely stopped intervening (n = 25) and one will continue receiving messages through the mobile app, but will no longer have workshops and food plan prescriptions (n = 25).
The use of dentistry in forensic medicine has gradually become an indispensable tool in the process of identifying human remains. In recent years, there has been a significant increase in the importance of this field in the identification of victims in mass disasters, criminal investigations, ethnic research, and the identification of decomposed and distorted bodies, such as drowning, fire and car accident victims. Dental examinations allow for precise determination of individual identities based on unique dental features. Various methods applied in forensic medicine in the realm of dentistry include dental impressions, radiographs, photographic examinations, rugoscopy, cheiloscopy, and molecular methods. Advanced dental analysis techniques make it possible to restore identities even in the most challenging cases. Equally important is the integration of knowledge and methods of forensic dentistry with other forensic disciplines such as molecular genetics and anthropology. Further research and development in this branch of science are crucial for improving investigative processes and ensuring the dignity of mass disaster victims. The aim of this work is to present methods using teeth for the identification of human remains along with the latest advancements in forensic DNA technology, which utilizes dental evidence to aid in the identification of human remains.
This study enrolled 150 patients planned for CC, and randomly assigned for one of the three groups. Group (A)include 49 patients who received two atorvastatin dose 80 mg 12 hours before CC and 40 mg just before CC. Group (B) include 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continue for 24hrs after the day of CC, Group (C) include 47 patients who only hydrated with saline. All included patients were hydrated with saline intravenous 0.9 sodium chloride (NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization. Serum creatinine(Scr), blood urea nitrogen (BUN) and estimated glomerular filtration rate were evaluated at the baseline and after 48 from CC. Serum neutrophil-associated lipocalin (NGAL) was evaluated after 4 hours from CC.
For the TRE group, we will restrict the eating window to 8 hours, where they will eat ad libitum. This is the same interval established by Dr. Panda and by our preliminary data. This interval will be entered into the mCC app and participants will be asked to adhere to this eating window during the intervention. All eating occasions will be logged using the mCC app. Only water and medications will be allowed outside of the eating window.
The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells. The patient was followed up and re-examined for 2 years postoperatively.
Compositions, kits, and methods for repairing bonds, for example, disulfide bonds, in hair or on the skin are disclosed. The compositions provide improved conditioning benefit for dry hair or moisturize the skin. The compositions also provide a long lasting moisturized feel and smooth feel to the skin or hair, without feeling greasy. The compositions contain one or more compounds that covalently bind at least two thiol groups in the hair or on the skin. Use of the binding compositions prevents reversion of the repaired bonds to their free thiol state, for at least one week or one month, or more, after a single application of the composition. Improved methods of styling hair, for example permanent hair waving, hair curling, hair coloring or highlighting and hair straightening, are also provided.
The invention discloses a nanometer medicine delivery system based on PPV virus-like particles and a preparation method and application of the nanometer medicine delivery system. The nanometer medicine delivery system is composed of a nanometer carrier material and medicine. The nanometer carrier material is PPV virus-like particles decorated by TK peptide and is prepared through a baculovirus expression system. The medicine is micromolecule antitumor medicine and is wrapped by and loaded with the nanometer carrier material in a wrapping or covalent linkage mode. The TK peptide is targeted peptide. The amino acid sequence of the TK peptide is TWYKIAFQRNRK. The TK peptide and virus-like particles (VLPs) formed by capsid protein VP2 of procine parvovirus (PPV) are connected together through a gene engineering method to form the nanometer carrier material (TK-VLPs). The nanometer carrier system is wrapped by and loaded with medicine to form an active targeting nanometer medicine delivery system, and the medicine carrying TK-VLPs nanometer medicine delivery system has good tumor targeting and a strong antitumor growth effect, can better mediate nanometer medicine delivery system targeting tumor tissue, and has good research and application prospects.
Clomiphene citrate is a common treatment for ovulation induction in subfertile women, but its use is associated with elevated risk of adverse perinatal outcomes and birth defects. To investigate the biological plausibility of a causal relationship, this study investigated the consequences in mice for fetal development and pregnancy outcome of periconception clomiphene citrate administration at doses approximating human exposures. A dose-dependent adverse effect of clomiphene citrate given twice in the 36 hours after mating was seen, with a moderate dose of 0.75 mg/kg sufficient to cause altered reproductive outcomes in 3 independent cohorts. Viable pregnancy was reduced by 30%, late gestation fetal weight was reduced by 16%, and ∼30% of fetuses exhibited delayed development and/or congenital abnormalities not seen in control dams, including defects of the lung, kidney, liver, eye, skin, limbs, and umbilicus. Clomiphene citrate also caused a 30-hour average delay in time of birth, and elevated rate of pup death in the early postnatal phase. In surviving offspring, growth trajectory tracking and body morphometry analysis at 20 weeks of age showed postweaning growth and development similar to controls. A dysregulated inflammatory response in the endometrium was observed and may contribute to the underlying pathophysiological mechanism. These results demonstrate that in utero exposure to clomiphene citrate during early pregnancy can compromise implantation and impact fetal growth and development, causing adverse perinatal outcomes. The findings raise the prospect of similar iatrogenic effects in women where clomiphene citrate may be present in the periconception phase unless its use is well-supervised.
PURPOSE:To provide a collagen metabolism-activating agent acting on human fibroblasts for enhancing their collagen-producing ability lowered by a pathogenic cause or a physiological cause such as aging. CONSTITUTION:The collagen metabolism-activating agent contains a sulfuric acid hydrolysate of silk fibers having a mol.wt. of <=500. A hydrolysate produced by directly adding 40-60vol.% of sulfuric acid to scoured silk fibers and treating the scoured silk fibers at 60 deg.C for 1-48hr or a hydrolysate produced by preliminarily treating the silk fibers with calcium chloride, etc., and subsequently adding sulfuric acid to the solution of the produced solubilized fibroin. etc., can be used as the sulfuric acid hydrolysate of the silk fiber. This collagen metabolism-activating agent is employed in the forms of various preparations such as a solution, a solid agent and a semi-solid agent, and the addition amount of the collagen metabolism-activating agent is usually 0.1-10wt.%, preferably 1-5wt.%, based on a composition to be applied, in the case of the activating agent containing 0.5-4wt.% of the hydrolysate as the silk fibers.
The present embodiments provide an antibody or antigen binding fragment that binds to the helicobacter pylori antigen protein urease, the antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region. Wherein the heavy chain variable region comprises CDRH1 with an amino acid sequence shown as SEQ ID NO. 2, CDRH2 with an amino acid sequence shown as SEQ ID NO. 3 and CDRH with an amino acid sequence shown as SEQ ID NO. 4. The light chain variable region comprises CDRL1 with the amino acid sequence shown in SEQ ID NO. 6, CDRL2 with the amino acid sequence shown in DTS and CDRL3 with the amino acid sequence shown in SEQ ID NO. 7. The antibody or antigen binding fragment has the characteristics of high purity, high specificity and high sensitivity. The embodiments of the present disclosure also provide related uses of antibodies or antigen binding fragments that bind to the helicobacter pylori antigen protein urease.
Patients in the supine position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
BACKGROUND: Sepsis is a leading cause of paediatric mortality worldwide, disproportionately affecting children in low- and middle-income countries. The impacts of climate change on the burden and outcomes of sepsis in low- and middle-income countries, particularly in paediatric populations, remain poorly understood. We aimed to assess the associations between climate variables (temperature and precipitation) and paediatric sepsis incidence and mortality in Bangladesh, one of the countries most affected by climate change.
METHODS: We conducted retrospective analyses of patient-level data from the International Centre for Diarrhoeal Disease Research, Bangladesh, and environmental data from the National Oceanic and Atmospheric Administration. Using random forests, we assessed associations between sepsis incidence and sepsis mortality with temperature and precipitation between 2009-22.
RESULTS: A nonlinear relationship between temperature and sepsis incidence and mortality was identified. The lowest incidence occurred at an optimum temperature of 26.6°C with a gradual increase below and a sharp rise above this temperature. Higher precipitation levels showed a general trend of increased sepsis incidence. A similar distribution for sepsis mortality was identified with an optimum temperature of 28°C.
CONCLUSIONS: Findings suggest that environmental temperature and precipitation play a role in paediatric sepsis incidence and sepsis mortality in Bangladesh. As children are particularly vulnerable to climate impacts, it is important to consider climate change in health care planning and resource allocation, especially in resource-limited settings, to allow for surge capacity planning during warmer and wetter seasons. Further prospective research from more globally representative data sets will provide more robust evidence on the nature of the relationships between climate variables and paediatric sepsis worldwide.
PURPOSE: Unexpected positive cultures are defined as a single positive culture in intraoperative samples taken during revision surgery after prosthetic joint infection was preoperatively ruled out. This study aims to determine the prevalence of unexpected positive cultures (UPC) in revision total knee arthroplasty (TKA) after unicompartmental knee arthroplasty (UKA). As a secondary objective, this study aims to compare the re-intervention rate in this specific group, between UPC and non-UPC patients. The hypothesis is that the UPC prevalence in patients who undergo a revision TKA after UKA is not higher than in other TKA revision cases and this does not increase the risk of re-intervention.
METHODS: This is a retrospective study where all patients who underwent a UKA revision from January 2016 to February 2023 in a high-volume arthroplasty centre, were analyzed. Unexpected positive culture prevalence in this group of patients was obtained.
RESULTS: During the included period, 270 UKA revision surgeries were performed. Eight cases had at least two positive cultures and were therefore excluded. The final analysis included 262 patients. Of these, 8 (3.05%) patients presented UPCs and the isolated microorganisms were low-virulence organisms. None of the UPC patients received any treatment. No statistical differences were found between UPC and non-UPC groups in the analyzed variables.
CONCLUSION: The prevalence of unexpected positive cultures in patients following revision of unicompartmental knee arthroplasty is lower than in patients who undergo a revision of total knee arthroplasty. In UKA patients a UPC does not seem to increase the risk of a re-intervention, so it can be safely ignored if ICM criteria are not met.
The method can be applied in the premedical assistance, in the inpatient and outpatient practice in the human and veterinary medicine for the effective treatment of diseases, in particular of diseases of the gastrointestinal, renal and urinary tract, of viral and bacterial infections. By the method the clinoptlilolite mineral is administered in combination with vitamin C. The clinoptiilolite is heat-treated at 150-250 degrees C, sterilized and has particle sizes of the particles of ? 0.1 mm. For the treatment of internal diseases the clinoptilolite is administered once daily at 0.5 to 1 teaspoons (2.5 to 5 g), 30 min to 4 h after meals. For the treatment of gum bleeding, colds, neuralgia, allergies, urticaria, hay fever, contagious diseases such as measles, varicella, rubeola, as well as medicamentous and intestinally intoxication, night wetting, uneasiness and strain, physical and mental fatigue, stress conditions, memory disorders (tendencies to absent-mindedness and forgetting), initial forms of the Alzheimer's disease, Gana, tendencies of diabetes and chronic alcoholism the organism should be cleaned in advance of toxic protein waste products. Then the organism is saturated with vitamin C under control until the satisfaction of its individual needs by periodic vitamin C administration of daily doses of from 0.5 to 5 g. The saturation moment is determined by periodic monitoring of the organism 4 h after each vitamin C administration, until reaching vitamin C level in the urine from 40 to 60 mg %. After the pre-saturation ends, this level is maintained by a vitamin C dose of from 0.1 to 0.5 daily until the restoration of normal anisotropic and isotropic crystalline structures in the patient's urine. In the treatment of other diseases another medicamentous form can be additionally administered depending on the treated diseases. 7 claims, 3 figures